Evidence map›Paper›PMID 30603708›Full record

ArticleHeliyon2018

An ameloblastin C-terminus variant is present in human adipose tissue.

Øystein Stakkestad, Catherine Heyward, Ståle Petter Lyngstadaas, Tirill Medin, Jiri Vondrasek, Aina-Mari Lian, Gita Pezeshki, Janne Elin Reseland

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Øystein StakkestadDepartment of Biomaterials, Institute of Clinical Dentistry, University of Oslo, Norway.
Catherine HeywardDepartment of Biomaterials, Institute of Clinical Dentistry, University of Oslo, Norway.
Ståle Petter LyngstadaasDepartment of Biomaterials, Institute of Clinical Dentistry, University of Oslo, Norway.
Tirill MedinDepartment of Nursing and Health Promotion, Faculty of Health Sciences, OsloMet - Oslo Metropolitan University, Norway.
Jiri VondrasekDepartment of Bioinformatics, Institute of Organic Chemistry and Biology, Czech Academy of Sciences, Prague, Czech Republic.
Aina-Mari LianDepartment of Biomaterials, Institute of Clinical Dentistry, University of Oslo, Norway.
Gita PezeshkiDepartment of Biomaterials, Institute of Clinical Dentistry, University of Oslo, Norway.
Janne Elin ReselandDepartment of Biomaterials, Institute of Clinical Dentistry, University of Oslo, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTranscriptional regulatory elements in the ameloblastin (AMBN) promoter indicate that adipogenesis may influence its expression. The objective here was to investigate if AMBN is expressed in adipose tissue, and have a role during differentiation of adipocytes.

design

resultsAMBN was found to be expressed in human adipose tissue, human primary adipocytes, and in 3T3-L1 cells. The C-terminus of the AMBN protein and a 45 bp shorter splice variant was identified in human subcutaneous adipose tissue. The expression of AMBN was found to increase four-fold during differentiation of 3T3-L1 cells. Administration of recombinant AMBN reduced the proliferation, and enhanced the expression of PPARγ and leptin in 3T3-L1 and human pre-adipocytes, respectively.

conclusionsThe AMBN C-terminus variant was identified in adipocytes. This variant may be encoded from a short splice variant. Increased expression of AMBN during adipogenesis and its effect on adipogenic factors suggests that AMBN also has a role in adipocyte development.

Indexed as

BiochemistryCell biologyMolecular biologyPhysiology

Identifiers

PMID30603708
PMCPMC6307104

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.